# B3GALT2

## Overview
B3GALT2 is a gene that encodes the enzyme beta-1,3-galactosyltransferase 2, which is a crucial component of the glycosyltransferase family. This enzyme is involved in the glycosylation process, a post-translational modification that is essential for the proper function of proteins and lipids. Beta-1,3-galactosyltransferase 2 specifically catalyzes the transfer of galactose to N-acetylglucosamine, contributing to the formation of glycoproteins and glycolipids. The enzyme is active in the Golgi apparatus and plays a significant role in cellular processes such as cell-cell communication, protein stability, and immune response. Alterations in B3GALT2 expression have been linked to various diseases, including Alzheimer's and Parkinson's, where it may influence disease progression through its impact on glycosylation pathways (Tang2023Transcriptomic; Schneider2022Altered). Additionally, B3GALT2 has been implicated in tumor progression in thymoma and is associated with immune responses in bladder urothelial cancer (Zhang2023Role; Xu2022Clinical).

## Function
B3GALT2 encodes the enzyme beta-1,3-galactosyltransferase 2, which plays a crucial role in the glycosylation process, a post-translational modification essential for the proper function of proteins and lipids. This enzyme specifically catalyzes the transfer of galactose to N-acetylglucosamine, forming part of the core structure of glycoproteins and glycolipids. Glycosylation is vital for cell-cell communication, protein stability, and immune response. B3GALT2 is active in the Golgi apparatus, where it contributes to the synthesis of complex carbohydrates (Tang2023Transcriptomic).

In the context of Alzheimer's disease, B3GALT2, along with B3GALT5, is involved in generating type-1 LacNAc units, which are prevalent in O-glycans and glycosphingolipids in humans. The differential expression of these genes in Alzheimer's disease suggests their potential role in disease-specific glycosylation alterations (Tang2023Transcriptomic).

In the nervous system, B3GALT2 is important for the development of neurons and glial cells. It has been implicated in maintaining neuronal integrity and function, potentially through its involvement in glycosylation processes and signaling pathways like Reelin, which is crucial for neuronal organization (Jia2021β1).

## Clinical Significance
Alterations in the expression of the B3GALT2 gene have been implicated in several diseases. In Parkinson's disease (PD), B3GALT2 expression is significantly increased in the substantia nigra, a brain region affected by the disease. This upregulation is associated with neuroinflammatory responses, as B3GALT2 is involved in protein glycosylation processes that regulate microglial activation. Knockdown of B3GALT2 has been shown to reduce levels of inflammatory cytokines TNFα and IL-6, suggesting its role in neuroinflammation and PD pathophysiology (Schneider2022Altered).

In Alzheimer's disease (AD), changes in B3GALT2 expression have been observed in multiple brain regions, indicating a broader alteration in glycosylation pathways. This suggests that B3GALT2, along with other galactosyltransferases, may contribute to the disease's progression by affecting glycan structures involved in cellular communication and immune responses (Tang2023Transcriptomic).

Elevated expression of B3GALT2 has also been noted in thymoma, a type of tumor originating from the thymus gland. This suggests a potential role in tumor progression, although specific mechanisms remain unclear (Zhang2023Role). Additionally, B3GALT2 is associated with bladder urothelial cancer, where it is part of a gene module linked to eosinophil-related immune responses and prognostic predictions (Xu2022Clinical).


## References


[1. (Xu2022Clinical) Chaojie Xu, Lishan Song, Hui Peng, Yubin Yang, Yi Liu, Dongchen Pei, Jianhua Guo, Nan Liu, Jiabang Liu, Xiaoyong Li, Chen Li, and Zhengjun Kang. Clinical eosinophil-associated genes can serve as a reliable predictor of bladder urothelial cancer. Frontiers in Molecular Biosciences, July 2022. URL: http://dx.doi.org/10.3389/fmolb.2022.963455, doi:10.3389/fmolb.2022.963455. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2022.963455)

[2. (Zhang2023Role) Xin Zhang, Bo Zeng, Haoshuai Zhu, Rui Ma, Ping Yuan, Zhenguang Chen, Chunhua Su, Zhihao Liu, Xiaojing Yao, Aurora Lawrence, Zhenguo Liu, and Jianyong Zou. Role of glycosphingolipid biosynthesis coregulators in malignant progression of thymoma. International Journal of Biological Sciences, 19(14):4442–4456, 2023. URL: http://dx.doi.org/10.7150/ijbs.83468, doi:10.7150/ijbs.83468. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/ijbs.83468)

[3. (Jia2021β1) Mengjie Jia, Xue Yang, Tianhui Yang, Xinyang Deng, Jia Liang, Jing Bi, and Peng Wang. Β-1, 3-galactosyltransferase 2 deficiency exacerbates brain injury after transient focal cerebral ischemia in mice. Brain Research Bulletin, 169:104–111, April 2021. URL: http://dx.doi.org/10.1016/j.brainresbull.2021.01.010, doi:10.1016/j.brainresbull.2021.01.010. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.brainresbull.2021.01.010)

[4. (Schneider2022Altered) Jay S. Schneider and Garima Singh. Altered expression of glycobiology-related genes in parkinson’s disease brain. Frontiers in Molecular Neuroscience, November 2022. URL: http://dx.doi.org/10.3389/fnmol.2022.1078854, doi:10.3389/fnmol.2022.1078854. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnmol.2022.1078854)

[5. (Tang2023Transcriptomic) Xinyu Tang, Jennyfer Tena, Jacopo Di Lucente, Izumi Maezawa, Danielle J. Harvey, Lee-Way Jin, Carlito B. Lebrilla, and Angela M. Zivkovic. Transcriptomic and glycomic analyses highlight pathway-specific glycosylation alterations unique to alzheimer’s disease. Scientific Reports, May 2023. URL: http://dx.doi.org/10.1038/s41598-023-34787-4, doi:10.1038/s41598-023-34787-4. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-023-34787-4)